Molecular structure of SE 175, CAS Number: 258278-64-7
SE 175 (CAS 258278-64-7)
Alternate Names:
2-[[4-[(nitrooxy)methyl]benzoyl]thio]-benzoic acid, methyl ester
Application:
SE 175 is a potential NO donor
CAS Number:
258278-64-7
Molecular Weight:
347.34
Molecular Formula:
C16H13NO6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SE 175 is an organic nitrate compound of the same general class as nitroglycerin. These nitrate compounds can act as NO-donors in vivo following reductive transformation of the nitrate group to nitric oxide. The nitroxyacylated thiosalicylates, such as SE 175, were developed in an effort to facilitate this reductive process and accelerate the release of NO. SE 175 is stable in buffer or saline solution. In the intact rat, it stimulates endothelial soluble guanylate cyclase and induces aortic vasorelaxation with an EC50 of 20 µM, which is intermediate in potency between nitroglycerine and isosorbide dinitrate.1
SE 175 (CAS 258278-64-7) References
- NO-Donors, part 3: nitrooxyacylated thiosalicylates and salicylates - synthesis and biological activities(#). | Endres, S., et al. 1999. Eur J Med Chem. 34: 895-901. PMID: 10889315
- Regulation of Endothelin-1-Induced Trabecular Meshwork Cell Contractility by Latanoprostene Bunod. | Cavet, ME., et al. 2015. Invest Ophthalmol Vis Sci. 56: 4108-16. PMID: 26114488
- The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. | Cavet, ME. and DeCory, HH. 2018. J Ocul Pharmacol Ther. 34: 52-60. PMID: 28783422
- Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy. | Cureton, N., et al. 2017. Theranostics. 7: 3715-3731. PMID: 29109771
- Placenta-targeted treatment strategies: An opportunity to impact fetal development and improve offspring health later in life. | Ganguly, E., et al. 2020. Pharmacol Res. 157: 104836. PMID: 32344051
- Dynamic placenta-on-a-chip model for fetal risk assessment of nanoparticles intended to treat pregnancy-associated diseases. | Shojaei, S., et al. 2021. Biochim Biophys Acta Mol Basis Dis. 1867: 166131. PMID: 33766738
- Hypoxia and Mitochondrial Dysfunction in Pregnancy Complications. | Hu, XQ. and Zhang, L. 2021. Antioxidants (Basel). 10: PMID: 33800426
- Targeted drug delivery for maternal and perinatal health: Challenges and opportunities. | Sharma, A., et al. 2021. Adv Drug Deliv Rev. 177: 113950. PMID: 34454979
- Nanomedicines: An approach to treat placental insufficiency and the current challenges. | van Kammen, CM., et al. 2023. J Control Release. 360: 57-68. PMID: 37330012
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SE 175, 5 mg | sc-205506 | 5 mg | $60.00 | |||
SE 175, 10 mg | sc-205506A | 10 mg | $114.00 |